Are you surprised that a device that costs $600 and that, by most accounts, isn’t essential to work or possibly even your entertainment is purchased by people with lots of disposable income who might be inclined to blow that disposable income on other equally useless things (apps)?
Well, some people are – specifically, those who look at how much iPad users buy when they’re not blowing their cash on iPads. To be fair, Yudu media’s analysis of the “Selling power of the iPad” at least quantifies the profligate spending habits of technology’s early adopters.
That’s great, and it’s clear other tablet makers want to capitalize on that market – after all, the Motorola XOOM, which is apparently the best thing in the world (since the iPad), is going to cost $800. But when does this market reach saturation? Tablets are still an unstable category, and it’s not clear that they won’t go the way of netbook sales at some point – especially if they don’t become cheaper.
And that’s where things get interesting. Does a tablet purchased from Walgreens for $100 grant its user the same magic purchasing power as an iPad? Of course not – it’s catering to a completely different demographic. And so, as tablets become democratized, they’ll become no more, or less, lucrative as a mechanism for delivering media or purchasing experiences than the computers they supplant. One of Apple’s secrets is that the app stores for the iPad and to a lesser extent the iPhone / iPod Touch are proprietary walled gardens disproportionately inhabited by the wealthy and/or spendthrift.
Yet for tablets to succeed, they must come down in price: witness the success of Amazon’s Kindle in the wake of the downward revision of its price. Johnny-come-lately tablet makers and everyone who would sell their wares on these devices should be wary of anyone arguing that tablets are necessarily a route to riches: they can be, but only to the extent that they remain a plaything of the economic elite.
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.